MetaCap

ANI Pharmaceuticals (ANIP) vs Damora Therapeutics (DMRA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Damora Therapeutics (DMRA) has outperformed ANI Pharmaceuticals (ANIP) over the past year, gaining 38.5% versus a loss of 14.0%. Over five years, ANIP leads with a +68.1% price change compared with -68.8% for DMRA. ANI Pharmaceuticals is the larger company by market cap ($1.56 billion vs $1.44 billion), about 1.1 times the size.

On valuation, Damora Therapeutics trades at a lower trailing P/E (13.6x vs 13.9x for ANI Pharmaceuticals).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIP-14.01%DMRA+38.46%
+110%+44%-21%
Nov 21, 20251 yearNov 20, 2026
ANIP+57.44%DMRA-69.04%
+135%+14%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIP versus DMRA key metrics
MetricANIPDMRA
Share price$68.55$23.22
Market cap$1.56B$1.44B
1-day change-0.84%-4.44%
YTD return-13.16%+0.91%
1-year return-14.01%+38.46%
5-year return+68.14%-68.83%
P/E ratio (TTM)13.9013.58
Forward P/E6.72—
EPS (TTM)$4.93$1.71
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$883.37M—
Revenue growth (YoY)+43.78%—
Net income (latest FY)$78.34M$-209.84M
Gross margin61.36%—
Operating margin12.58%—
Net margin8.87%—
52-week high$87.76$38.33
52-week low$67.14$15.76
Distance from 52-week high-21.89%-39.41%
Analyst consensusbuystrong_buy
Avg. price target upside+50.81%+101.46%
Average volume420.66K584.28K
Shares outstanding22.72M61.90M
Employees9707
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DMRA has outperformed ANIP by 52.5 percentage points over the past year.

About ANI Pharmaceuticals

ANIP stock →

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products.

Health Care · Biotechnology: Pharmaceutical Preparations · 970 employees

About Damora Therapeutics

DMRA stock →

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

ANIP vs DMRA FAQ

Which is bigger, ANI Pharmaceuticals or Damora Therapeutics?

ANI Pharmaceuticals (ANIP) is larger, with a market capitalization of $1.56B compared with $1.44B for Damora Therapeutics (DMRA).

Which stock has performed better over the past year, ANIP or DMRA?

DMRA returned +38.46% over the past 12 months, compared with -14.01% for ANIP (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, ANIP or DMRA?

DMRA has the lower trailing P/E at 13.6, versus 13.9 for ANIP. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are ANI Pharmaceuticals and Damora Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons